期刊
MOLECULAR PSYCHIATRY
卷 20, 期 2, 页码 152-153出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/mp.2014.139
关键词
-
资金
- NHMRC [1059660, 1056929]
- NIH
- Simons Autism Foundation
- Cancer Council of Victoria
- CRC for Mental Health
- Stanley Medical Research Foundation
- MBF
- Beyond Blue
- Geelong Medical Research Foundation
- Bristol Myers Squibb
- Eli Lilly
- GlaxoSmithKline
- Organon
- Novartis
- Mayne Pharma
- Servier
- Brain and Behaviour Foundation (NARSAD)
- Canadian Institute of Health Research
- State of Minnesota
- National Health and Medical Research Council of Australia [1056929] Funding Source: NHMRC
There is currently considerable imprecision in the nosology of biomarkers used in the study of neuropsychiatric disease. The neuropsychiatric field lags behind others such as oncology, wherein, rather than using 'biomarker' as a blanket term for a diverse range of clinical phenomena, biomarkers have been actively classified into separate categories, including prognostic and predictive tests. A similar taxonomy is proposed for neuropsychiatric diseases in which the core biology remains relatively unknown. This paper divides potential biomarkers into those of (1) risk, (2) diagnosis/trait, (3) state or acuity, (4) stage, (5) treatment response and (6) prognosis, and provides illustrative exemplars. Of course, biomarkers rely on available technology and, as we learn more about the neurobiological correlates of neuropsychiatric disorders, we will realize that the classification of biomarkers across these six categories can change, and some markers may fit into more than one category.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据